glp·helper
glphelper.com/wegovy/california/santa-barbara
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Santa Barbara, CA

Verified Wegovy providers in Santa Barbara, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
36
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
37 of 37 shown

Find an Wegovy provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /wegovy/california/{city}
§ 03Getting Wegovy in Santa Barbara
37 providers · Santa Barbara, CA

How to get Wegovy in Santa Barbara.

37 GLP-1 prescribers and 7 local resource types are on record for Santa Barbara, plus 3 nearby towns in the directory.

Prescribers in Santa Barbara
37 prescribers
37 GLP-1 prescribers in Santa Barbara, most listed as Family Medicine (14), Internal Medicine, Endocrinology, Diabetes & Metabolism (12) and Internal Medicine (9). Any California-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Oxnard (27 providers), Thousand Oaks (35 providers) and Santa Maria (30 providers).
Around the prescription in Santa Barbara
7 listed nearby
70 dietitians, 8 nutritionists, 6 gyms, 4 fitness clubs, 4 trainers, 6 physiotherapists and 6 places to move are on record near Santa Barbara.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Santa Barbara

Santa Barbara, California has a population of 88,665 people. The adult obesity rate in Santa Barbara is an age-adjusted estimate of 26.4%, 2.7 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 9.1% of adults in Santa Barbara. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 20.8% of adults in Santa Barbara.

of Santa Barbara adults have obesity
26.4%
diagnosed diabetes
9.1%
no regular physical activity
20.8%

Age-adjusted estimates for Santa Barbara, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossoral and sublingual GLP-1 options
§ 05Support around Wegovy in Santa Barbara
6 dietitians

The prescription is one part. Here is the rest, in Santa Barbara.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Santa Barbara, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Nicole Almanza, RD, CDCES, CHES
RD
Registered dietitian
215 Pesetas Ln
Call 805-681-7820NPI 1316594781
Christina Archer, MS, RD
RD
Registered dietitian
317 W Pueblo St
Call 805-681-7500NPI 1487178380
Maria Arellano
RD
Registered dietitian
2125 Centerpointe Pkwy
Call 805-346-8246NPI 1194943753
Rachel Astorga-Regalado, RD
RD
Registered dietitian
916 San Andres St Apt A
Call 805-944-0151NPI 1730899675
Lauren Beltran, RDN
RD
Registered dietitian
4141 State St
Call 805-681-7144NPI 1790556736
Jane Boone-Brechwald
RD
Registered dietitian
2125 Centerpointe Pkwy
Call 805-346-8467NPI 1538387196

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Chris Latham, Nutritionist
NUTRITIONIST
Nutritionist
4760 Amarosa Street
Call 805-451-7058NPI 1467961722
Candyce Torrez, MScN
NUTRITIONIST
Nutritionist · Education
62 Willow Springs Ct Apt 202
Call 805-701-4824NPI 1598494395
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in California

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]